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TO THE EDITOR
I read with great interest the article by
Hiscutt et al. (2010) entitled ‘‘X-Linked
Inhibitors of Apoptosis Protein as a
Therapeutic Target in Metastatic Mela-
noma.’’ The data presented indicate
that X-linked inhibitor of apoptosis
protein (XIAP) could serve as a target
to inhibit the growth of melanoma cells.
A key objective of the study was to
examine the relationship between XIAP
expression and mutations in N-RAS
and B-RAF. To achieve this goal, the
authors examined N-RAS and B-RAF
mutations in 49 melanoma samples and
found no correlation between muta-
tions in these genes and the expres-
sion of XIAP. This lack of correlation
may be due to the fact that the
49 melanoma samples were hetero-
geneous with respect to tumor type
and AJCC stage. Although the authors
mention that they did separate analyses
with AJCC stages Ib, II, and III, the
groups were still heterogeneous and did
not account for differences in tumor
type. For example, tumors of stage IIA,
IIB, and IIC from superficial spread-
ing malignant melanoma, nodular
malignant melanoma, and acral lenti-
ginous melanoma were all linked
together in the same analysis. This
heterogeneity could have masked an
association between XIAP expression
and mutations in N-RAS and B-RAF that
may be present in a particular AJCC
stage and tumor type. While I can
appreciate the difficulty in obtaining
enough samples for each tumor type
and AJCC stage, the conclusion that
there is no significant correlation bet
ween XIAP expression and mutations in
N-RAS and B-RAF is not justified.
Considering the limitations in ob-
taining sufficient samples of different
tumor types and AJCC stages, a better
way to establish a relationship between
N-RAS/B-RAF mutations and the ex-
pression of XIAP could be to study this
phenomenon in cell lines. This ap-
proach is feasible because, as the
authors have shown in Figure 1, this
protein is highly expressed in three of
the five cell lines that were evaluated.
Indeed, the authors used a knockdown
of XIAP in A375 cells to establish its
role in apoptosis. A similar approach
could have been used to examine
XIAP’s relationship with mutations in
N-RAS/B-RAF. Using this approach,
for example, the authors could have
obtained definitive answers on the
effect of V600E B-RAF mutations
on XIAP expression because selective
inhibitors of V600E B-RAF are available
(Flaherty et al., 2010).
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TO THE EDITOR
Tissue injury initiates a complex series
of events that act to restore tissue
structure and homeostasis. Infiltration
of inflammatory cells and vascular
remodeling are both keystones of this
process. However, the role of inflam-
mation and angiogenesis and particu-
larly the significance of vascular
endothelial growth factor (VEGF) in this
context are unclear. Studies of dermal
wound healing have delivered conflict-
ing results on the benefit of inflamma-
tory cell infiltration and release of
VEGF, in both wound closure and
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subsequent scar formation (Wilgus
et al., 2008). Microvascular neoforma-
tion is traditionally regarded as crucial
for sustained perfusion and metabolism
during the wound-healing process
(Tonnesen et al., 2000; Ferrara, 2002).
Recently, reports have challenged this
model, postulating that release of VEGF
and subsequent angiogenesis might
have a negative impact on wound
healing (Wilgus et al., 2008).
To address these issues and to define
the role of VEGF in the inflammatory
response during wound healing, we
generated a tissue-specific deletion of
the angiogenic factor VEGF-A in mye-
loid lineage cells (Stockmann et al.,
2008). Mice with both alleles of exon 3
of VEGF-A flanked by loxP sites
(VEGFþ f/þ f) (Gerber et al., 1999)
were crossed into a background of cre
recombinase expression driven by the
lysozyme M promoter (LysMCre/
VEGFþ f/þ f) (Clausen et al., 1999).
To determine the role of myeloid
cell-derived VEGF in a model of exci-
sional wound healing, we performed
8mm circular punch biopsies on the
back skin of wild-type (WT) and VEGF
mutant (Mut) mice. Compared with
WT littermates, we found that wound
closure was delayed in Mut mice
(Figure 1a). This delay in healing is
due to reduction in the number of
proliferating dermal as well as epithe-
lial cells at the wound margin that
precedes the delay in wound closure
(Figure 1b and c).
In order to quantify vascularization
of the wounds, we performed immuno-
staining for the presence of endothelial
cells. At day 8 post-injury, preceding
the delay in wound healing, there were
significantly fewer (B50%) capillaries
in the wound margins of Mut mice
relative to WT mice (Figure 1d and e).
Thus, loss of VEGF in myeloid cells
results in insufficient revascularization
of wounds.
Among wound-infiltrating cells,
macrophages represent a major popu-
lation that is also known for its ability
to release large amounts of VEGF
(Berse et al., 1992; Nissen et al.,
1998). Although we did not observe
any genotype-specific differences in
myeloid cell infiltration of the wounds
(data not shown), we aimed to deter-
mine whether the reduced vessel den-
sity observed in Mut mice is potentially
a result of reduced VEGF levels within
the wound margin. Visualization of
VEGF by immunofluorescence showed
significant reduction in VEGF levels in
the wound margins of VEGF Mut mice
relative to WT mice (Figure 1f and g),
which precedes the impaired neovas-
cularization seen in these animals.
Myofibroblasts are known to have
a role in wound contraction to support
wound closure. During granulation
tissue formation, the number of smooth
muscle actin-a (SMA-a)-expressing
myofibroblasts increases. When the
wound is fully epithelialized, myofibro-
blasts progressively disappear. In con-
trast, myofibroblasts persist during
abberant healing and scarring (Darby
et al., 1990). In order to determine the
effect of inflammatory cell-derived
VEGF on the presence of myofibroblasts
after completion of wound closure, we
performed immunofluorescence for
SMA-a at day 14 post-wounding and
quantified SMA-a-positive cells that are
not associated with blood vessels in
order to exclude SMA-a-positive peri-
cytes from the analysis. Whereas myo-
fibroblasts were almost absent in WT
animals, the skin from Mut animals
showed higher levels of SMA-a-positive
cells (Figure 1h and i), indicating an
earlier stage of the healing process with
persistent myofibroblasts due to de-
layed re-epithelialization and resolu-
tion of wounds that heal in the absence
of inflammatory cell-derived VEGF.
Owing to the diversity in models of
cutaneous wound healing, we applied
another common model of cutaneous
wound healing. In this model, long-
itudinal incisions are performed and the
wound margins are immediately re-
attached (Wilgus et al., 2008). Interest-
ingly, in this model we could not detect
any genotype-specific differences in
wound healing, as assessed by the
measurement of the scar width (Figure
2a and b). The visualization of endo-
thelial structures within these wounds
showed a rather low vessel density
and did not reveal genotype-specific
differences (Figure 2c and d). Further-
more, there were no differences in
VEGF expression or myofibroblast num-
bers in incisional wounds from WT and
Mut animals (Figure 2e and f). These
observations argue that neoangiogen-
esis driven by inflammatory cell-
derived VEGF does not contribute to
scar tissue deposition in incisional
wounds, but is particularly essential
for the rapid formation of granulation
tissue and lateral keratinocyte expan-
sion during the healing of large cuta-
neous defects.
Many wound-healing studies of full-
thickness cutaneous wounds such as
those employed in this study suggest
that the release of VEGF and subse-
quent angiogenesis is beneficial for
wound healing, whereas a reduction
of angiogenesis can impair the healing
rates. In contrast, some reports suggest
that modulation of VEGF-induced an-
giogenesis does not affect healing rates
to a large degree (Bao et al., 2009). This
controversy about the role and outcome
of neoangiogenesis during wound heal-
ing and scar formation, and in particu-
lar the confusion about the impact of
VEGF in this context, could be largely
due to the use of different models of
wound healing with different readout
parameters. Indeed, a recent study
using a model of incisional wounds
reported that VEGF-driven angiogenesis
contributes to scar formation (Wilgus
et al., 2008). Conversely, when we
assessed the effect of loss of VEGF in
myeloid cells on the healing of inci-
sional wounds, we did not detect
differences in healing or scar formation.
Importantly, incisional wounds, owing
to immediate re-attachment of wound
edges, likely depend less on vessel
sprouting than do excisional wounds.
Therefore, the importance of myeloid
cell-derived driven angiogenesis might
not become apparent in this model.
Interestingly, we have recently shown
that the loss of VEGF in myeloid cells
aggravates pulmonary fibrosis (Stockmann
et al., 2010), a process thought to be
closely linked to an abberant healing
response and excessive scarring. Although
this intuitively appears to be in strong
contrast to the results presented here, we
would like to point out that in both
settings loss of myeloid cell-derived VEGF
leads to impaired re-epithelialization by
alveolar epithelial cells and keratinocytes,
respectively, as well as increased numbers
of myofibroblasts. This observation further
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Figure 1. Reduced vessel density and delayed healing of excisional skin wounds in VEGF mutant (Mut) mice. (a) Closure of 8mm circular wounds on the back
skin of wild-type (WT) and vascular endothelial growth factor (VEGF) Mut mice (n¼11). (b) Quantitative analysis of proliferating dermal cells at the wound
margin 8 days post-wounding (n¼ 6). (c) Quantitative analysis of proliferating keratinocytes at the wound margin 8 days post-wounding (n¼6). (d) CD34
immunostaining at day 8 post-wounding. (e) Chalkley analysis of vessel density at day 8 post-wounding (n¼ 6). (f) Immunostaining for VEGF in wound tissue at
day 6 post-wounding. (g) Quantitative analysis of the area positive for VEGF at day 6 post-wounding (n¼6). (h) Immunodetection of smooth muscle actin (SMA)-
positive myofibroblasts within wounds at day 14 post-wounding. (i) Quantitative analysis of myofibroblasts at day 14 post-wounding (n¼6). Error bars show
SEM. PCNA, proliferating cell nuclear antigen. Bar¼ 100 mm.
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indicates that VEGF expression by mye-
loid cells is a crucial aspect of tissue
restoration.
A study of loss of VEGF tissue, speci-
fically in keratinocytes, confirmed
the crucial role of VEGF in healing of
excisional wounds, showing retarded
resolution (Rossiter et al., 2004). Taken
together, this argues that a coordinated
expression of VEGF from both tissue/
cell types is necessary for the healing of
excisional wounds and further empha-
sizes our notion that different models of
wound healing render the various
studies difficult to compare.
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Figure 2. Myeloid cell–derived vascular endothelial growth factor (VEGF) does not affect the healing of incisional skin wounds. (a) Hematoxylin and eosin
(H&E) staining of incisional wounds from wild-type (WT) and mutant (Mut) mice at day 12 post-wounding. (b) Quantitative analysis of the scar width of
incisional wounds at day 12 post-wounding (n¼ 8). (c) CD34 immunostaining of incisional wounds at day 12 post-wounding. (d) A quantitative analysis of CD
34-positive blood vessels in WT and Mut animals at day 12 post-wounding (n¼ 8). (e) Quantitative analysis of the area covered by VEGF within scars of
incisional wounds at day 12 post-wounding (n¼ 8). (f) Quantitative analysis of the smooth muscle actin (SMA)-positive area within scars of incisional wounds at
day 12 post-wounding (n¼8). Error bars show SEM. Bar¼100 mm.
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